A virtue of using small interfering RNAs as therapeutics is their exquisite specificity. But when it comes to inhibiting blood-vessel growth, it seems that they can act generically without even entering a cell.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nyberg, P., Xie, L. & Kalluri, R. Cancer Res. 65, 3967–3979 (2005).
Folkman, J. Nature Rev. Drug Discov. 6, 273–286 (2007).
Kleinman, M. E. et al. Nature 452, 591–597 (2008).
Akira, S. Adv. Immunol. 78, 1–56 (2001).
Medzhitov, R. & Janeway, C. Jr Immunol. Rev. 173, 89–97 (2000).
Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Nature 413, 732–738 (2001).
Lin, Y., Liang, Z., Chen, Y. & Zeng, Y. J. Immunol. 176, 4147–4154 (2006).
Lang, K. S. et al. J. Clin. Invest. 116, 2456–2463 (2006).
Cameron, J. S. et al. J. Neurosci. 27, 13033–13041 (2007).
Rights and permissions
About this article
Cite this article
Kalluri, R., Kanasaki, K. Generic block on angiogenesis. Nature 452, 543–545 (2008). https://doi.org/10.1038/452543a
This article is cited by
Antitumor effect of RNA interference on non-small-cell lung cancer in vivo
The Chinese-German Journal of Clinical Oncology (2009)